No Data
No Data
junshi bio (01877.HK) plans to hold a board of directors meeting on October 29 to approve quarterly performance.
Gelonghui, October 17th | junshi bio (01877.HK) announced that the board of directors hereby notifies that a board meeting will be held on October 29, 2024 (Tuesday) to consider and approve the unaudited financial performance of the group for the nine months ended September 30, 2024.
JUNSHI BIO: DATE OF BOARD MEETING
Shanghai Junshi Biosciences Gets Approval to Market Immunotherapy Drug in Hong Kong, China
Express News | Shanghai Junshi Biosciences - Unit Granted Certificate of Drug/Product Registration Issued by Pharmacy and Poisons Board of Hong Kong
Junshi Bio (01877.HK): Toripalimab has been approved for listing in China Hong Kong.
On October 15th, Junshi Bio (01877.HK) announced that its wholly-owned subsidiary, Topalliance Biosciences Hong Kong Limited, recently obtained the 'Drug/Product Registration Certificate' issued by the Pharmacy and Poisons Board (PPB) in Hong Kong. The certificate approves a combination of Toripalimab (commodity name in Hong Kong: LOQTORZI) with cisplatin/gemcitabine as first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, as well as monotherapy.
Express News | Junshi Biosciences Announces Toripalimab Obtained Approval for Marketing in India and China’s Hong Kong SAR
No Data
No Data